Navigation Links
Can-Fite Proceeds with Development of Third Drug; Progress in,Development of CF502 Will Be Presented at the Annual European,Congress of Rheumatology

PETACH TIKVA, Israel--(BUSINESS WIRE)--Jun 14, 2007 - Can-Fite BioPharma (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange Exchange, proceeds with the development of its third drug CF502; this is in addition to CF101, which is currently in clinical trials and CF102, which is in preclinical phases. This weekend Can-Fite will present at the EUALR annual congress of rheumatology in-vitro and in vivo study results showing effective anti-inflammatory activity for CF502. The EUALR congress is highly regarded and attracts global leaders in the Rheumatology arena.

The chemical structure of CF502 differs from that of the Company's first two drugs CF101 and CF102, and is characterized by higher affinity and selectivity to the A3 adenosine receptor, which is targeted by the Can-Fite's drugs. The drug attacks inflammatory cells and leads to programmed cell death (apoptosis) and suppression of the inflammatory process. Can-Fite is using human cells to investigate the effects and mechanism of action of CF502. The Company is currently finalizing the development of CF502 synthesis process, before entering preclinical and clinical development phases.

Can-Fite will present at the rheumatology congress in-vitro data showing that CF502 specifically targets inflammatory cells and does not affect healthy cells, and will also present the drug's molecular mechanism of action. In addition in vivo data showing marked anti-inflammatory effects of CF502 will be reported. The Company will also present new data on the expression of A3 adenosine receptor in various autoimmune diseases. High expression of this receptor is directly correlated with response of inflammatory cells to this drug.

Prof. Pnina Fishman, CEO of Can-Fite: "I am pleased with the rapid progress in the CF502 development program and with the in-vitro and in vivo trial results showing impressive anti-inflammatory activity for this drug. Elucidation of CF502 mechanism of action and the ability to examine this activity in human cells improve the chances that this drug can offer effective treatment for patients."

CF502, which is being developed by Can-Fite, became part of the development pipeline after Can-Fite had signed a prestigious agreement with the NIH, the leading research institute in the US. Under this agreement, titled CRADA, Can-Fite now cooperates with the laboratory of Prof. Jacobson, a worldwide leading scientist in the field of A3 adenosine receptor agonists and antagonists. Can-Fite is currently in negotiations with the NIH for the licensing of the CF502 molecule.

In addition to CF502, Can-Fite's development pipeline also includes two other drugs, CF101 which is being evaluated for rheumatoid arthritis, dry eye syndrome and psoriasis in phase I clinical trials, and CF102 which is intended for the treatment of liver cancer and hepatitis B. The Company's first commercial agreement was signed with the Japanese Seikagaku Corporation during development of CF101, under the terms of which Can-Fite has already received about USD 5 million.

CAN-FITE BIOPHARMA LTD is a public company traded on the Tel Aviv Stock Exchange. The Company, which commenced business activity in 2000, was founded by researcher Prof. Pnina Fishman and patent attorney Dr. Ilan Cohn. The Company focuses on the development of molecule-based drugs that inhibit the development of cancer or inflammatory cells. The market for the company's drugs is estimated at billions of dollars.

Contact

Can-Fite BioPharma
Pnina Fishman, Ph.D., +972-3-9241114
Chief Executive Officer
Fax: +972-3-9249378
pnina@canfite.co.il
http://www.canfite.com/


'"/>




Related medicine technology :

1. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
2. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
3. Anadys Pharmaceuticals Nominates ANA598, a Small-Molecule, Non-Nucleoside Inhibitor of The NS5b Polymerase, as a Candidate for Clinical Development in Chronic Hepatitis C Virus Infection
4. Ambrilia Highlights Encouraging Data for its HIV Integrase Inhibitor Program and Recent Developments at Annual Meeting
5. CuraGen Presents Update on Clinical Development Program for Belinostat
6. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
7. DURECT Provides an Update to the Memryte Program Under Development by Voyager Pharmaceutical Corp
8. ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting
9. Alnylam Announces Advancement of a New RNAi Therapeutic Development Program for the Treatment of Liver Cancer
10. Biomira Selects PX-866 as Clinical Development Candidate and Presents Promising Preclinical Data at AACR
11. Newly Released Canadian Data Links Vaccines with Pervasive Developmental Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... 20, 2017 Entscheidung ... Nothilfe   Die internationale humanitäre Stadt soll um ... schaffen   Seine Hoheit Scheich Muhammad ... sowie Herrscher von Dubai , hat ... Hilfe (International Humanitarian City IHC) zu verdreifachen, um den ...
(Date:1/20/2017)... 20, 2017 Avillion LLP, a co-developer and ... Mark Weinberg , MD MBA as Chief Medical Officer. Dr Weinberg ... USA . ... Dr Weinberg has spent more than 17 years as a pharmaceutical ... to micro-cap biotech. Over the course of his career, he has ...
(Date:1/19/2017)... -- Germany Cataract Surgery Devices Market ... "Germany Cataract Surgery Devices Market Outlook to 2022", provides ... market. The report provides value, in millions of US ... market segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic Devices ... distribution shares data for each of these market segements, ...
Breaking Medicine Technology:
(Date:1/20/2017)... ... ... Hawkins, Pastor and Overseer at The House of Yahweh has posted a new publication this ... generation is a time like no other and society needs to understand the only way ... does not want to sound like an old bible beater because religion has a bad ...
(Date:1/20/2017)... ... January 20, 2017 , ... Source Vitál Apothecary, a ... percent pure essential oils, announced the company had a successful visit to the 2017 ... ECRM event gives companies that work in the nutritional, sports and health industries a ...
(Date:1/20/2017)... ... January 20, 2017 , ... Doctor C LLC, a company based out ... trade show to continue the marketing and distribution of its product, The Right C. ... 400 percent better absorption than traditional vitamin C supplements. At the trade show, Doctor ...
(Date:1/20/2017)... ... ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality nutritional ... ECRM Trade Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures its ... products to all clients at reasonable prices. At the ECRM trade show, it had ...
(Date:1/20/2017)... ... January 20, 2017 , ... Lice Troopers, the lice removal company based ... school-aged children since the holiday season. , “It happens every year around this ... hugs and taking photos, which is the head-to-head gateway that lice need to spread.” ...
Breaking Medicine News(10 mins):